Butriptyline

Structural formula
	Structural formula without stereochemistry
General
Non-proprietary name	Butriptyline
other names	( RS ) -10,11-dihydro- N , N , beta-trimethyl-5 H -dibenzo [ a , d ] cyclohepten-5-propylamine ( IUPAC ); (±) -10,11-dihydro- N , N , beta-trimethyl-5 H -dibenzo [ a , d ] cycloheptene-5-propylamine;
Molecular formula	C 21 H 27 N; C 21 H 27 N · HCl ( hydrochloride );
External identifiers / databases
PubChem	21772
ChemSpider	20462
DrugBank	DB09016
Wikidata	Q904524
Drug information
ATC code	N06 AA15
Drug class	Tricyclic antidepressant
properties
Molar mass	293.45 g mol −1 ; 329.92 g mol −1 (hydrochloride);
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
Toxicological data	700 mg kg −1 ( LD 50 , rat , oral , hydrochloride) ; 345 mg kg −1 ( LD 50 , mouse , oral , hydrochloride) ; 48 mg kg −1 ( LD 50 , mouse , iv , hydrochloride) ;
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Butriptyline is a drug belonging to the group of tricyclic antidepressants . The mechanism of action is similar to amitriptyline . At the same dose, however, it is said to have a more effective antidepressant effect than amitriptyline, without having more side effects. It develops its maximum effect (T _max ) after 2.6 (unretarded) to 7.5 hours (retarded). The plasma half-life is 20 hours.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ ^a ^b ^c A. Kleemann , J. Engel, B. Kutscher, D. Reichert: Pharmaceutical Substances - Synthesis, Patents, Applications , 4th edition (2000), Thieme-Verlag Stuttgart, ISBN 978-1-58890-031- 9 .
↑ Guelfi JD; Dreyfus, JF; Delcros, M .; Pichot, P .: A double-blind controlled multicenter trial comparing butriptyline with amitriptyline. In: Neuropsychobiology. (971983), pp. 142-146; PMID 6353270 .
↑ Bourgouin, J .; Gagnon, MA; Elie, R .; Dvornik, D .; Gonzalez, R .; Kraml, M .: Butriptyline: human pharmacokinetics and comparative bioavailability of conventional and sustained release formulations. In: Biopharm Drug Dispos . (2/1981), pp. 123-130, PMID 6894708 .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Kleemann-2] A. Kleemann , J. Engel, B. Kutscher, D. Reichert: Pharmaceutical Substances - Synthesis, Patents, Applications , 4th edition (2000), Thieme-Verlag Stuttgart, ISBN 978-1-58890-031- 9 .

[3] Guelfi JD; Dreyfus, JF; Delcros, M .; Pichot, P .: A double-blind controlled multicenter trial comparing butriptyline with amitriptyline. In: Neuropsychobiology. (971983), pp. 142-146; PMID 6353270 .

[4] Bourgouin, J .; Gagnon, MA; Elie, R .; Dvornik, D .; Gonzalez, R .; Kraml, M .: Butriptyline: human pharmacokinetics and comparative bioavailability of conventional and sustained release formulations. In: Biopharm Drug Dispos . (2/1981), pp. 123-130, PMID 6894708 .